Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02166905IINY-ESO-1+ or LAGE-1+ ovarian cancer with or without residual disease after treatmentA Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 AntigenNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CDX-1401DEC-205/NY-ESO-1 fusion protein CDX-1401Immune response against cancer expressing NY-ESO-1Clinical Trials
EpacadostatIDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360Inhibits IDO1 to stimulate immune responseClinical Trials
NCT04239014IIRecurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapyA Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance TreatmentContact research study staffView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.